The FDA has cleared BeOne Medicines’ BCL2 blocker sonrotoclax for the treatment of certain patients with mantle cell lymphoma ...

The BCL-2 inhibitor was granted accelerated approval based on findings from the phase 1/2 BGB-11417-201 study.

The U.S. Food and Drug Administration (FDA) on Wednesday granted accelerated approval to BeOne Medicines Ltd.‘s ONC Beqalzi ...

Sonrotoclax (Beqalzi) indicated for relapsed or refractory mantle cell lymphoma ...

FDA accelerated approval covers relapsed/refractory MCL after ≥2 lines including a BTK inhibitor, positioning sonrotoclax as ...

Beqalzi (sonrotoclax) is the first BCL2 inhibitor indicated for MCL patients who have progressed after at least 2 lines of therapy, including a BTK inhibitor.

By Siddhi Mahatole and Puyaan Singh May 13 (Reuters) - BeOne Medicines said on Wednesday that the U.S. Food and Drug ...

BeOne Medicines Ltd. ("BeOne") (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. To be honest, very good progress has been ...

Translocations are chromosomal “cut and paste” errors that drive many lymphomas, a type of blood cancer and the sixth most common form of cancer overall. This includes mantle cell lymphoma, a rare but ...

Researchers at Karolinska Institutet have discovered that mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer, is already highly diverse at the time of diagnosis and continues to ...

The study covers the period of 2015-2019 in Germany, before approvals for CAR T-cell therapy, pirtobrutinib, and the arrival of less toxic BTK inhibitors. UK real-world data show that bridging therapy ...